skip to main content
Guest
My Research
My Account
Sign out
Sign in
This feature requires javascript
Library Search
Find Databases
Browse Search
E-Journals A-Z
E-Books A-Z
Citation Linker
Help
Language:
English
Vietnamese
This feature required javascript
This feature requires javascript
Primo Search
All Library Resources
All
Course Materials
Course Materials
Search For:
Clear Search Box
Search in:
All Library Resources
Or hit Enter to replace search target
Or select another collection:
Search in:
All Library Resources
Search in:
Print Resources
Search in:
Digital Resources
Search in:
Online E-Resources
Advanced Search
Browse Search
This feature requires javascript
Search Limited to:
Search Limited to:
Resource type
criteria input
All items
Books
Articles
Images
Audio Visual
Maps
Graduate theses
Show Results with:
criteria input
that contain my query words
with my exact phrase
starts with
Show Results with:
Search type Index
criteria input
anywhere in the record
in the title
as author/creator
in subject
Full Text
ISBN
ISSN
TOC
Keyword
Field
Show Results with:
in the title
Show Results with:
anywhere in the record
in the title
as author/creator
in subject
Full Text
ISBN
ISSN
TOC
Keyword
Field
This feature requires javascript
Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention
Circulation. Cardiovascular interventions, 2022-03, Vol.15 (3), p.e011382-e011382
[Peer Reviewed Journal]
ISSN: 1941-7640 ;EISSN: 1941-7632 ;DOI: 10.1161/CIRCINTERVENTIONS.121.011382 ;PMID: 35209731
Full text available
Citations
Cited by
View Online
Details
Recommendations
Reviews
Times Cited
External Links
This feature requires javascript
Actions
Add to My Research
Remove from My Research
E-mail
Print
Permalink
Citation
EasyBib
EndNote
RefWorks
Delicious
Export RIS
Export BibTeX
This feature requires javascript
Title:
Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention
Author:
Furtado, Remo H M
;
Fagundes, Jr, Antônio Aurélio
;
Oyama, Kazuma
;
Zelniker, Thomas A
;
Tang, Minao
;
Kuder, Julia F
;
Murphy, Sabina A
;
Hamer, Andrew
;
Wang, Huei
;
Keech, Anthony C
;
Giugliano, Robert P
;
Sabatine, Marc S
;
Bergmark, Brian A
Subjects:
Antibodies, Monoclonal, Humanized - therapeutic use
;
Anticholesteremic Agents - therapeutic use
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
;
Myocardial Infarction - prevention & control
;
Percutaneous Coronary Intervention - adverse effects
;
Proprotein Convertase 9 - therapeutic use
;
Risk Factors
;
Treatment Outcome
Is Part Of:
Circulation. Cardiovascular interventions, 2022-03, Vol.15 (3), p.e011382-e011382
Description:
Patients with prior percutaneous coronary intervention (PCI) are at high residual risk for multiple types of coronary events within and beyond the stented lesion. This risk might be mitigated by more intensive LDL-C (low-density lipoprotein cholesterol)-lowering beyond just with statin therapy. FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) randomized 27 564 patients with stable atherosclerotic disease on statin to the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab or placebo with a median follow-up of 2.2 years. The end points of interest were major adverse cardiovascular events (MACE; a composite of cardiovascular death, myocardial infarction, stroke, unstable angina or coronary revascularization), and major coronary events (a composite of coronary heart death, myocardial infarction, or coronary revascularization). We compared the risk of MACE and the magnitude of relative and absolute risk reductions with evolocumab in patients with and without prior PCI. Seventeen thousand seventy-three patients had prior PCI. In the placebo arm, those with prior PCI had higher rates of MACE (13.2% versus 8.3%; hazard ratio [HR] 1.61 [95% CI, 1.42-1.84]; <0.0001) and major coronary events (11.5% versus 6.0%; HR , 1.72 [95% CI, 1.49-1.99]; <0.0001). Relative risk reductions with evolocumab were similar in patients with and without prior PCI (MACE: HR, 0.84 [0.77-0.91] versus HR, 0.88 [0.77-1.01]; 0.51; major coronary events: HR, 0.82 [0.75-0.90] versus HR, 0.88 [0.75-1.04]; 0.42). Absolute risk reductions for MACE were 2.0% versus 0.9% ( 0.14) and for major coronary events 2.0% versus 0.7% ( 0.045). In those with prior PCI, the effect of evolocumab on coronary revascularization (HR, 0.76 [0.69-0.85]) was directionally consistent across types of revascularization procedures: coronary artery bypass grafting (HR, 0.71 [0.54-0.94]); any PCI (HR, 0.77 [0.69-0.86]); PCI for de novo lesions (HR, 0.76 [0.66-0.88]); and PCI for stent failure or graft lesions (HR, 0.76 [0.63-0.91]). Evolocumab reduces the risk of MACE in patients with prior PCI including the risk of coronary revascularization, with directionally consistent effects across several types of revascularization procedures, including coronary artery bypass grafting and PCI for stent or graft failure. URL: https://www. gov; Unique identifier: NCT01764633.
Publisher:
United States
Language:
English
Identifier:
ISSN: 1941-7640
EISSN: 1941-7632
DOI: 10.1161/CIRCINTERVENTIONS.121.011382
PMID: 35209731
Source:
MEDLINE
Alma/SFX Local Collection
This feature requires javascript
This feature requires javascript
Back to results list
This feature requires javascript
This feature requires javascript
Searching Remote Databases, Please Wait
Searching for
in
scope:(TDTS),scope:(SFX),scope:(TDT),scope:(SEN),primo_central_multiple_fe
Show me what you have so far
This feature requires javascript
This feature requires javascript